Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.33 |
| ▸ | TUBB | P07437 | 3/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316368 | 0.84 | ENPP2 (0.41) | ENPP2TUBB1LMNAMAPK1HTT | |
| SCHEMBL29408115 | 0.83 | ENPP2 (0.43) | ENPP2TUBB1LMNAMAPK1HTT | |
| SCHEMBL789623 | 0.83 | ENPP2 (0.43) | ENPP2TUBB1LMNAMAPK1HTT | |
| SCHEMBL3480772 | 0.83 | ENPP2 (0.46) | ENPP2TUBB1ORAI1ORAI2ORAI3 | |
| SCHEMBL5859114 | 0.81 | ENPP2 (0.45) | ENPP2TUBB1ORAI1ORAI2ORAI3 | |
| SCHEMBL29956202 | 0.81 | ENPP2 (0.45) | ENPP2TUBB1ORAI1ORAI2ORAI3 | |
| SCHEMBL30154767 | 0.79 | ENPP2 (0.43) | ENPP2TUBB1LMNAMAPK1HTT | |
| SCHEMBL12097369 | 0.79 | ENPP2 (0.43) | ENPP2TUBB1LMNAMAPK1HTT | |
| SCHEMBL30905956 | 0.78 | ENPP2 (0.39) | ENPP2LMNAMAPK1HTTRAB9A | |
| SCHEMBL6082901 | 0.78 | ENPP2 (0.39) | ENPP2LMNAMAPK1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-7238690-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060178362-A1 | Substituted heterocyle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-08-10 | — | — | US | disclosed |
| US-7081455-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-25 | — | — | US | disclosed |
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | disclosed |
| EP-1189905-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | ROBICHAUD ALBERT J (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-6548493-B1 | Serotonin receptor modulators (5-HT2C and 5-HT2A); treating obesity, anxiety, depression, psychological disorders, migraine, sexual disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | ENPP2 2236/4885TUBB1 2203/4885LMNA 4575/4885 |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | ENPP2 3904/4885TUBB1 2009/4885LMNA 1683/4885 |
| US-20060178362-A1 | Substituted heterocyle fused gamma-carbolines | HTR2B, HTR1B, HTR3B | ENPP2 3070/4885TUBB1 1707/4885LMNA 1196/4885 |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | ENPP2 1232/4885TUBB1 3735/4885LMNA 3639/4885 |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | HTR2C, HTR2B, HTR3B | ENPP2 2934/4885TUBB1 2702/4885LMNA 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.